COMMUNIQUÉS West-GlobeNewswire

Quotient Board Announces Contract Extension of CEO Franz Walt
02/07/2019
JERSEY, Channel Islands, July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Board of [...]
Blueberries Executes Definitive Agreement to Acquire Cannabis Cultivation, Processing & Manufacturing Rights for 3.2M Square Foot Property in Argentina
02/07/2019
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Further to its news releases dated March 26 and April 4, 2019, Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “ Company ” or " Blueberries "), a leading [...]
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
02/07/2019
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer SAN CARLOS, Calif., July 02, 2019 (GLOBE NEWSWIRE) -- Iovance [...]
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
02/07/2019
Promising signs of clinical efficacy without increase in LDL cholesterol SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of [...]
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
02/07/2019
Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 02, 2019 ( [...]
TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology
02/07/2019
Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company [...]
Helius Medical Technologies to Release Second Quarter of Fiscal Year 2019 Financial Results on August 8, 2019
02/07/2019
NEWTOWN, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that second [...]
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
02/07/2019
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting [...]
ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
02/07/2019
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada
02/07/2019
Endo product line available in over 200 natural health product stores VANCOUVER, British Columbia, July 02, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), through its [...]
Pluristem Therapeutics’ CEO Issues Shareholder Letter
02/07/2019
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an [...]
Aleafia Health Secures Health Canada Permits to Export Cannabis Products to Australia
02/07/2019
Permits Allow Company to Begin its First International Cannabis Product Shipment Products to be Distributed by Australian-based Strategic Partner CannaPacific TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Aleafia Health [...]
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus
02/07/2019
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus Clinical relevance of data [...]
SV Health Investors announces the appointment of Jonathan Behr, PhD as Partner in the Dementia Discovery Fund
02/07/2019
SV Health Investors announces the appointment of Jonathan Behr, PhD as Partner in the Dementia Discovery Fund Former founding managing director of JDRF T1D Fund joins DDF leadership team London, 2 July 2019 - The [...]
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
02/07/2019
CONSHOHOCKEN, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as [...]
Exactus, Inc. Provides Update On It’s Farming Activities At Exactus One World In Cave Junction, Oregon
02/07/2019
DELRAY BEACH, Fla., July 02, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) (the “Company”), a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, is pleased to announce that the [...]
Molina Healthcare Announces Second Quarter 2019 Earnings Release and Conference Call Dates
02/07/2019
LONG BEACH, Calif., July 02, 2019 (GLOBE NEWSWIRE) -- Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the second quarter ended June 30, 2019. Molina Healthcare will issue [...]
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance
02/07/2019
Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa Guidance for Total 2019 Revenue Increased to a Range of $380 to $420 Million from $350 Million Following Unaudited Second Quarter Results [...]
Adjustment of timeline for FDA decision regarding application for pediatric clinical use of The NGAL Test™
02/07/2019
July 2, 2019 Announcement no. 12 Adjustment of timeline for FDA decision regarding application for pediatric clinical use of The NGAL Test™ BioPorto A/S (“BioPorto”) announces today that the timeline for the company’s [...]

Pages